Tracy Robson

Tracy Robson

Head of Department

Tracy Robson obtained her PhD in Cancer Biology from Imperial College, London. Her first academic post was as Lecturer in Radiation Science at Ulster University in 1997; she was promoted to Reader in 2001. She then moved to the School of Pharmacy, Queen’s University of Belfast in 2004 to take up the post of Reader in Molecular Pharmacology; she was promoted to Professor in 2010. In 2016, she took up position as Professor and Head of Department of Molecular and Cellular Therapeutics at RCSI. Her major focus has been in the tumour biology field.  She led a major programme of research aimed at the identification and functional characterisation of genes that alter tumour biology.  In particular, she cloned and characterized a novel human gene, FKBPL. Her group has demonstrated that FKBPL was a naturally secreted, anti-angiogenic protein. Together with Almac Discovery, she led the development of therapeutic peptide derivatives (AD-01 and ALM201) based on FKBPL’s active anti-angiogenic domain. Based on the robust efficacy and excellent safety profile, ALM201, a ‘first-in-class’ FKBPL-based anti-angiogenic therapeutic peptide has successfully completed a phase I cancer clinical trial (EudraCT number: 2014-001175-31).  ALM201 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in the treatment of ovarian cancer in 2017. More recently, through the development of genetically modified mouse models, she demonstrated a role for FKBPL in protection against obesity, with FKBPL deficient mice becoming severely obese. Her research is now focussing on unravelling the associated mechanisms driving FKBPL’s protective activity in obesity (as well as cancer) so that the clear translational potential of FKBPL-based therapeutics can be fully harnessed and FKBPL’s diagnostic potential in these disease settings can be utililized.

Tracy Robson

Head of Department

Dr. Stephanie Annett
Position: Postdoctoral Researcher & Honorary Lecturer

Stephanie is a post doctoral scientist, funded by NCRC and is conducting research on FKBPL’s role in childhood obesity.

Dr. Gillian Moore
Position: Postdoctoral Researcher

Gillian is a postdoctoral researcher investigating the anti-cancer activity of FKBPL and drug peptide derivatives. She is funded by Almac Discovery.

Unravelling the role of FKBPL in Childhood Obesity

Amongst Irish children, there has been a dramatic two-to-four fold increase in obesity since 1990; 1 in 5 Irish children are now obese. As these children grow into obese adults, they are seven times more likely to become a type 2 diabetic or develop heart disease and cancer.To further investigate the biology underlying obesity in children, we have identified a novel role for a specific protein, called FKBPL, which regulates blood vessels that can feed fat. Low levels of this protein also appear to promote fat development and stimulate immune cells exacerbating the problem. We will investigate how FKBPL influences obese pathology with a view to providing new diagnostic and treatment options for these children.Our co-investigators include: Dr Annie Curtis (RCSI) and Prof Declan Cody (OLCHC) and Dr Andrew Hogan (NCRC and Maynooth),

The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

McCrudden CM, McBride JW, McCaffrey J, McErlean EM, Dunne NJ, Kett VL, Coulter JA, Robson T, McCarthy HO, 2018, Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer. Cancer Nanotechnol, DOI: 10.1186/s12645-018-0040-x
Cole G, Ali AA, McCrudden CM, McBride JW, McCaffrey J, Robson T, Kett VL, Dunne NJ, Donnelly RF, McCarthy HO, 2018 Jun, DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system. Eur J Pharm Biopharm, DOI: 10.1016/j.ejpb.2018.02.029
Byrne T, Nelson L, Beirne JP, Sharpe D, Quinn JE, McCluggage WG, Robson T, Furlong F, 2018 Mar, BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma. Int J Gynecol Cancer, DOI: 10.1097/IGC.0000000000001214
Annett S, Robson T, 2018 Jul, Targeting cancer stem cells in the clinic: Current status and perspectives. Pharmacol Ther, DOI: 10.1016/j.pharmthera.2018.02.001
O'Sullivan JM, Preston RJS, Robson T, O'Donnell JS, 2018 Mar, Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Semin Thromb Hemost, DOI: 10.1055/s-0037-1607352
McCrudden CM, McBride JW, McCaffrey J, Ali AA, Dunne NJ, Kett VL, Coulter JA, Robson T, McCarthy HO, 2017 Mar 17, Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment. Mol Ther Nucleic Acids, DOI: 10.1016/j.omtn.2016.12.010
Ali AA, McCrudden CM, McCaffrey J, McBride JW, Cole G, Dunne NJ, Robson T, Kissenpfennig A, Donnelly RF, McCarthy HO, 2017 Apr, DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. Nanomedicine, DOI: 10.1016/j.nano.2016.11.019
Massey AS, Pentlavalli S, Cunningham R, McCrudden CM, McErlean EM, Redpath P, Ali AA, Annett S, McBride JW, McCaffrey J, Robson T, Migaud ME, McCarthy HO, 2016 Apr 4, Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA. Mol Pharm, DOI: 10.1021/acs.molpharmaceut.5b00670
McCaffrey J, McCrudden CM, Ali AA, Massey AS, McBride JW, McCrudden MT, Vicente-Perez EM, Coulter JA, Robson T, Donnelly RF, McCarthy HO, 2016 Mar 28, Transcending epithelial and intracellular biological barriers; a prototype DNA delivery device. J Control Release, DOI: 10.1016/j.jconrel.2016.02.023
McBride JW, Massey AS, McCaffrey J, McCrudden CM, Coulter JA, Dunne NJ, Robson T, McCarthy HO, 2016 Mar 16, Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer. Int J Pharm, DOI: 10.1016/j.ijpharm.2016.01.039
Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ, 2016 Feb 16, PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. Oncotarget, DOI: 10.18632/oncotarget.6955
Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ, 2016 Mar 1, Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, DOI: 10.1002/cncr.29814
Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, Collins B, Robson T, Scorfield S, Green K, Hall C, Liao XH, Ryan M, Johnson F, Stevens G, Kearins O, Sellars S, Patnick J, 2016 Jan, Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol, DOI: 10.1016/S1470-2045(15)00446-5
Bennett R, Yakkundi A, McKeen HD, McClements L, McKeogh TJ, McCrudden CM, Arthur K, Robson T, McCarthy HO, 2015 Oct, RALA-mediated delivery of FKBPL nucleic acid therapeutics. Nanomedicine (Lond), DOI: 10.2217/nnm.15.115
McClements L, Annett S, Yakkundi A, Robson T, 2015, The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases. Curr Mol Pharmacol, DOI: 10.2217/nnm.15.115
Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T, 2015 May 20, FKBPL: a marker of good prognosis in breast cancer. Oncotarget, DOI: 10.18632/oncotarget.3528
Jack RH, Robson T, Davies EA, 2016 Jun, The varying influence of socioeconomic deprivation on breast cancer screening uptake in London. J Public Health (Oxf), DOI: 10.1093/pubmed/fdv038
Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T, 2015 Apr, FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis. Arterioscler Thromb Vasc Biol, DOI: 10.1161/ATVBAHA.114.304539
Klem K, Holub P, Štroch M, Nezval J, Špunda V, Tříska J, Jansen MA, Robson TM, Urban O, 2015 Aug, Ultraviolet and photosynthetically active radiation can both induce photoprotective capacity allowing barley to overcome high radiation stress. Plant Physiol Biochem, DOI: 10.1016/j.plaphy.2015.01.001
Jack RH, Møller H, Robson T, Davies EA, 2014 Oct 16, Breast cancer screening uptake among women from different ethnic groups in London: a population-based cohort study. BMJ Open, DOI: 10.1136/bmjopen-2014-005586
McCarthy HO, McCaffrey J, McCrudden CM, Zholobenko A, Ali AA, McBride JW, Massey AS, Pentlavalli S, Chen KH, Cole G, Loughran SP, Dunne NJ, Donnelly RF, Kett VL, Robson T, 2014 Sep 10, Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J Control Release, DOI: 10.1016/j.jconrel.2014.06.048
Robson TC, Braungardt CB, Rieuwerts J, Worsfold P, 2014 Jan, Cadmium contamination of agricultural soils and crops resulting from sphalerite weathering. Environ Pollut, DOI: 10.1016/j.envpol.2013.09.001
Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM, McCarthy HO, Robson T, 2014 Jun 26, Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. Oncogene, DOI: 10.1038/onc.2013.306
McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T, 2013 Jul 15, Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-13-0595
Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T, 2013, The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One, DOI: 10.1371/journal.pone.0055075
Ali AA, Coulter JA, Ogle CH, Migaud MM, Hirst DG, Robson T, McCarthy HO, 2013 Mar 28, The contribution of N₂O₃ to the cytotoxicity of the nitric oxide donor DETA/NO: an emerging role for S-nitrosylation. Biosci Rep, DOI: 10.1042/BSR20120120
McCluskey AG, Mairs RJ, Sorensen A, Robson T, McCarthy HO, Pimlott SL, Babich JW, Champion S, Boyd M, 2013 Mar, Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter. Radiat Res, DOI: 10.1667/RR3030.1
Song L, Robson T, Doig T, Brenn T, Mathers M, Brown ER, Doherty V, Bartlett JM, Anderson N, Melton DW, 2013 Jan, DNA repair and replication proteins as prognostic markers in melanoma. Histopathology, DOI: 10.1111/j.1365-2559.2012.04362.x
Robson T, James IF, 2012 Jun, The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein. Drug Discov Today, DOI: 10.1016/j.drudis.2012.01.002
McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T, 2011 Apr, The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochem Soc Trans, DOI: 10.1042/BST0390663
Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D, 2011 Apr 20, Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol, DOI: 10.1200/JCO.2010.30.3677
Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T, 2011 Mar 1, FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-10-2241
Hirst DG, Robson T, 2011, Nitric oxide physiology and pathology. Methods Mol Biol, DOI: 10.1007/978-1-61737-964-2_1
McCarthy HO, Zholobenko AV, Wang Y, Canine B, Robson T, Hirst DG, Hatefi A, 2011 Feb 28, Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy. Int J Pharm, DOI: 10.1016/j.ijpharm.2010.11.051
Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO, 2010 Sep, Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med, DOI: 10.1002/jgm.1495
Robson T, West C, 2010 Aug, Radiation and the genome: from risks to opportunities for therapeutic exploitation. Br J Radiol, DOI: 10.1259/bjr/31552255
Hirst D, Robson T, 2010, Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy. Curr Pharm Des, DOI: 10.1259/bjr/31552255
Hirst DG, Robson T, 2010 Jan, Nitrosative stress as a mediator of apoptosis: implications for cancer therapy. Curr Pharm Des, DOI: 10.1259/bjr/31552255
Sunnotel O, Hiripi L, Lagan K, McDaid JR, De León JM, Miyagawa Y, Crowe H, Kaluskar S, Ward M, Scullion C, Campbell A, Downes CS, Hirst D, Barton D, Mocanu E, Tsujimura A, Cox MB, Robson T, Walsh CP, 2010 Mar 8, Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. Reprod Biol Endocrinol, DOI: 10.1186/1477-7827-8-22
McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T, 2010 Feb 1, FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res, DOI: 10.1158/0008-5472.CAN-09-2515
Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JM, 2009 Nov, Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience. Histopathology, DOI: 10.1111/j.1365-2559.2009.03419.x
Devlin AH, Thompson P, Robson T, McKeown SR, 2010 Feb, Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation. Mol Carcinog, DOI: 10.1002/mc.20589
Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ, 2009 Oct 1, Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-09-0398
Coleman MR, Davis MH, Rodd JM, Robson T, Ali A, Owen AM, Pickard JD, 2009 Sep, Towards the routine use of brain imaging to aid the clinical diagnosis of disorders of consciousness. Brain, DOI: 10.1093/brain/awp183
Adams C, McCarthy HO, Coulter JA, Worthington J, Murphy C, Robson T, Hirst DG, 2009 Feb, Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med, DOI: 10.1002/jgm.1280
McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ, McCarthy HO, Hirst DG, Robson T, 2008 Nov, A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology, DOI: 10.1210/en.2008-0168
McCarthy HO, Coulter JA, Robson T, Hirst DG, 2008 Aug, Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J Pharm Pharmacol, DOI: 10.1211/jpp.60.8.0007
Devlin AH, McIlroy M, McKeen HD, Bonde P, Menezes AA, Swarbrick CJ, Robson T, Hirst DG, Campbell FC, McGuigan JA, McKeown SR, 2009 Feb, Cytochrome P450 1B1 expression in rat esophageal tumorigenesis promoted by gastric and duodenal reflux. Mol Carcinog, DOI: 10.1002/mc.20459
Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D, Lawler M, Hirst DG, 2008 Sep, The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? J Gene Med, DOI: 10.1002/jgm.1221
Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, Worthington J, 2008 Aug 15, Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer, DOI: 10.1002/ijc.23418
Coulter JA, McCarthy HO, Xiang J, Roedl W, Wagner E, Robson T, Hirst DG, 2008 Sep, Nitric oxide--a novel therapeutic for cancer. Nitric Oxide, DOI: 10.1016/j.niox.2008.04.023
Litherland GJ, Dixon C, Lakey RL, Robson T, Jones D, Young DA, Cawston TE, Rowan AD, 2008 May 23, Synergistic collagenase expression and cartilage collagenolysis are phosphatidylinositol 3-kinase/Akt signaling-dependent. J Biol Chem, DOI: 10.1074/jbc.M710136200
O'Rourke M, Ward C, Worthington J, McKenna J, Valentine A, Robson T, Hirst DG, McKeown SR, 2008 Mar 1, Evaluation of the antiangiogenic potential of AQ4N. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-07-1262
Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S, Hirst DG, 2008 Apr, The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther, DOI: 10.1038/gt.2008.7
Hirst DG, Robson T, 2007 May 1, Nitrosative stress in cancer therapy. Front Biosci, DOI: 10.1038/gt.2008.7
McCarthy HO, Coulter JA, Worthington J, Robson T, Hirst DG, 2007 Jun, Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. J Gene Med, DOI: 10.1002/jgm.1045
Coutinho-Silva R, Robson T, Beales PE, Burnstock G, 2007 Mar, Changes in expression of P2X7 receptors in NOD mouse pancreas during the development of diabetes. Autoimmunity, DOI: 10.1080/08916930601118841
Hirst D, Robson T, 2007 Jan, Targeting nitric oxide for cancer therapy. J Pharm Pharmacol, DOI: 10.1211/jpp.59.1.0002
Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD, 2006 Oct, Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum, DOI: 10.1002/art.22167
McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG, Robson T, 2007 Feb, p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther, DOI: 10.1038/
Jasim ZF, Lioe TF, McKenna KE, Robson T, Ouhtit A, 2006 Feb, The effect of ultra violet B (TL-01) phototherapy on epidermal expression of p53 protein in psoriatic plaques. Photodermatol Photoimmunol Photomed, DOI: 10.1111/j.1600-0781.2006.00197.x
Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T, 2006 Jun, Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther, DOI: 10.1038/sj.cgt.7700933
McIlroy M, O'Rourke M, McKeown SR, Hirst DG, Robson T, 2006 Jan, Pericytes influence endothelial cell growth characteristics: role of plasminogen activator inhibitor type 1 (PAI-1). Cardiovasc Res, DOI: 10.1016/j.cardiores.2005.08.003
Robson T, Worthington J, McKeown SR, Hirst DG, 2005 Aug, Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity. Technol Cancer Res Treat, DOI: 10.1177/153303460500400404
Worthington J, Robson T, Scott S, Hirst D, 2005 Oct, Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Ther, DOI: 10.1038/
McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR, 2005 Jul, A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med, DOI: 10.1002/jgm.728
Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG, 2004, Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action. Oncol Res, DOI: 10.1002/jgm.728
McKeown SR, Ward C, Robson T, 2004 Aug, Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther, DOI: 10.1002/jgm.728
Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG, 2004 Jun, Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med, DOI: 10.1002/jgm.567
Dunne AL, Price ME, Mothersill C, McKeown SR, Robson T, Hirst DG, 2003 Dec 15, Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. Br J Cancer, DOI: 10.1038/sj.bjc.6601427
McKeown SR, Robson T, Price ME, Ho ET, Hirst DG, McKelvey-Martin VJ, 2003 Dec 15, Potential use of the alkaline comet assay as a predictor of bladder tumour response to radiation. Br J Cancer, DOI: 10.1038/sj.bjc.6601426
Coutinho-Silva R, Parsons M, Robson T, Lincoln J, Burnstock G, 2003 Jun 30, P2X and P2Y purinoceptor expression in pancreas from streptozotocin-diabetic rats. Mol Cell Endocrinol, DOI: 10.1038/sj.bjc.6601426
McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T, 2003 Jan, Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther, DOI: 10.1038/sj.cgt.7700522
Worthington J, Robson T, O'Keeffe M, Hirst DG, 2002 Feb, Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther, DOI: 10.1038/
Coutinho-Silva R, Parsons M, Robson T, Burnstock G, 2001 Dec, Changes in expression of P2 receptors in rat and mouse pancreas during development and ageing. Cell Tissue Res, DOI: 10.1007/s004410100458
Glass R, Bardini M, Robson T, Burnstock G, 2001, Expression of nucleotide P2X receptor subtypes during spermatogenesis in the adult rat testis. Cells Tissues Organs, DOI: 10.1159/000047905
Robson T, Blackwell D, Waine C, Kennedy RL, 2001 Apr, Factors affecting the use of dietetic services by patients with diabetes mellitus. Diabet Med, DOI: 10.1159/000047905
Chamary VL, Robson T, Loizidou M, Boulos PB, Burnstock G, 2000 Sep, Progressive loss of perivascular nerves adjacent to colorectal cancer. Eur J Surg Oncol, DOI: 10.1053/ejso.2000.0952
Al-Assar O, Robson T, McKeown SR, Gardin I, Wilson GD, Hirst DG, 2000 Nov, Regulation of FOS by different compartmental stresses induced by low levels of ionizing radiation. Radiat Res, DOI: 10.1053/ejso.2000.0952
Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG, 2000 Jul, Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther, DOI: 10.1053/ejso.2000.0952
Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin VJ, McKeown SR, Hirst DG, 2000 May, Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radioresistance. Int J Radiat Biol, DOI: 10.1053/ejso.2000.0952
Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S, 1999 Dec, Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des, DOI: 10.1053/ejso.2000.0952
Price ME, McKelvey-Martin VJ, Robson T, Hirst DG, McKeown SR, 2000 Jun, Induction and rejoining of DNA double-strand breaks in bladder tumor cells. Radiat Res, DOI: 10.1053/ejso.2000.0952
Martin AR, Bailie JR, Robson T, McKeown SR, Al-Assar O, McFarland A, Hirst DG, 2000 Jan, Retinal pericytes control expression of nitric oxide synthase and endothelin-1 in microvascular endothelial cells. Microvasc Res, DOI: 10.1006/mvre.1999.2208
Robson T, Joiner MC, Wilson GD, McCullough W, Price ME, Logan I, Jones H, McKeown SR, Hirst DG, 1999 Nov, A novel human stress response-related gene with a potential role in induced radioresistance. Radiat Res, DOI: 10.1006/mvre.1999.2208
Bailie JR, Robson TA, McCullough W, Hirst DG, 1997 Feb, Identification of the inducible nitric oxide synthase gene in macro- and microvascular endothelial cell lines. Biochem Soc Trans, DOI: 10.1006/mvre.1999.2208
Robson TA, Lohrer H, Bailie JR, Hirst DG, Joiner MC, Arrand JE, 1997 Feb, Gene regulation by low-dose ionizing radiation in a normal human lung epithelial cell line. Biochem Soc Trans, DOI: 10.1006/mvre.1999.2208
Joiner MC, Lambin P, Malaise EP, Robson T, Arrand JE, Skov KA, Marples B, 1996 Nov 4, Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat Res, DOI: 10.1006/mvre.1999.2208
Hoyle CH, Stones RW, Robson T, Whitley K, Burnstock G, 1996 Jun, Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. J Anat, DOI: 10.1006/mvre.1999.2208
Robson T, Grindley H, Hall A, Vormoor J, Lohrer H, 1994 Mar, Increased DNA-repair capacity and the modulation of 2 proteins in and metallothionein overexpressing Chinese hamster cell line. Mutat Res, DOI: 10.1006/mvre.1999.2208
Robson T, Hall A, Lohrer H, 1992 Sep, Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene. Mutat Res, DOI: 10.1006/mvre.1999.2208
Lohrer H, Robson T, Grindley H, Foster S, Hall A, 1990 Nov, Differential effects on cell killing in metallothionein overexpressing CHO mutant cell lines. Carcinogenesis, DOI: 10.1006/mvre.1999.2208
Lohrer H, Robson T, 1989 Dec, Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis, DOI: 10.1006/mvre.1999.2208
Giles CM, Uring-Lambert B, Goetz J, Hauptmann G, Fielder AH, Ollier W, Rittner C, Robson T, 1988, Antigenic determinants expressed by human C4 allotypes; a study of 325 families provides evidence for the structural antigenic model. Immunogenetics, DOI: 10.1006/mvre.1999.2208

Funding Agency: NCRC - Paediatric Research Project Grants 2018
Project Title:Unravelling the role of FKBPL in Childhood Obesity
Start Date/End Date:Sept 2018 - Aug 2021
Total Awarded:€262,000
Funding Agency:Almac Discovery
Project Title:Mechanistic insights into the anti-stemness activity of FKBPL-based peptides
Start Date/End Date:January 2017 - January 2019
Total Awarded:£200,000
Funding Agency:Invest NI Proof of Concept
Project Title:Tackling obesity with a new nanomedicine
Start Date/End Date:September 2016 - Sept 2018
Total Awarded:£106,000
Funding Agency:Invest NI Proof of Concept
Project Title:A new pro-angiogenic nanomedicine for chronic wound healing
Start Date/End Date:September 2016 - Sept 2018
Total Awarded:£106,000
Name:Professor Tim Harrison
Position:Vice President Discovery Chemistry
Institution:Almac Discovery Ltd.
Country:Northern Ireland
Name:Professor Helen McCarthy
DepartmentChairperson Phion & Professor, School of Pharmacy, QUB
Institution:Phion Therapeutics
Country:Northern Ireland

    Honours & Awards

    2015    Winner, inaugural PG Supervisory Excellence Award, QUB

    2013    Nominated and shortlisted for the Vice Chancellors Impact Prize, QUB.

    2011    Nominated and shortlisted for the World Technology Awards, within the Health and Medicine section; these awards are for those individuals doing innovative work of “the greatest likely long-term significance” in their fields; those “creating the 21st century”.

    1999    The Lunn’s Award of Excellence. Sponsored by Lunn’s (Northern Ireland). In recognition of services to heath, wealth and wellbeing of the people of Northern Ireland.

    Professional Associations:

    2010-present   Fellow of the Royal Society of Biology (nominated Fellow)

    1997-present   Member of the Association for Radiation Research, UK (ARR)

    2008-present   Member of the European Association for Cancer Research (EACR)

    2002-present   Member of the Irish Association for Cancer Research (IACR)

    2007-present   Member of the Irish Radiation Research Society (IRRS)